Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enanta Pharmaceuticals

6.30
+0.20003.28%
Post-market: 6.300.00000.00%16:08 EDT
Volume:278.22K
Turnover:1.72M
Market Cap:134.40M
PE:-1.27
High:6.32
Open:5.97
Low:5.93
Close:6.10
Loading ...

Enanta reports Q1 EPS ($1.05), consensus ($1.35)

TIPRANKS
·
11 Feb

BRIEF-Enanta Pharmaceuticals Q1 Revenue USD 16.959 Million

Reuters
·
11 Feb

Enanta Pharmaceuticals Q1 Operating Income USD -23.543 Million

THOMSON REUTERS
·
11 Feb

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Business Wire
·
11 Feb

Enanta Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview

Reuters
·
08 Feb

Enanta Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview

Reuters
·
04 Feb

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Zacks
·
23 Jan

U.S. RESEARCH ROUNDUP-BTCS, Gevo, ServiceNow

Reuters
·
24 Dec 2024

HC Wainwright Adjusts Price Target on Enanta Pharmaceuticals to $18 From $27, Maintains Buy Rating

MT Newswires Live
·
24 Dec 2024

Enanta to appeal ruling related to ‘953 patent infringement lawsuit

TIPRANKS
·
24 Dec 2024

Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer

Dow Jones
·
24 Dec 2024

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

THOMSON REUTERS
·
24 Dec 2024

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Business Wire
·
24 Dec 2024

Enanta Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
24 Dec 2024

Promising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment Concerns

TIPRANKS
·
24 Dec 2024

Enanta price target lowered to $18 from $27 at H.C. Wainwright

TIPRANKS
·
24 Dec 2024